Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
Posted: February 13, 2025 at 2:44 am
DOVER, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that on February 11, 2025, it received notification from The Nasdaq Stock Market, LLC (“Nasdaq”) that Nasdaq has accepted Portage’s compliance plan and has granted the Company the extension to regain compliance with the continued listing standards on The Nasdaq Capital Market (the “Capital Market”) as set forth in Nasdaq Listing Rule 5550(b)(1) whereby the minimum shareholders’ equity is at least $2.5 million or meet either of the alternative continued listing standards for the Capital Market, relating to market value of listed securities of at least $35 million or net income from continued operations of at least $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.
Continued here:
Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
Posted in Global News Feed
Comments Off on Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
Jade Biosciences to Participate in TD Cowen’s 45th Annual Health Care Conference and Jefferies Biotech on the Beach Summit
Posted: February 13, 2025 at 2:44 am
VANCOUVER, British Columbia and SAN FRANCISCO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in two upcoming investor conferences in March 2025:
See the article here:
Jade Biosciences to Participate in TD Cowen’s 45th Annual Health Care Conference and Jefferies Biotech on the Beach Summit
Posted in Global News Feed
Comments Off on Jade Biosciences to Participate in TD Cowen’s 45th Annual Health Care Conference and Jefferies Biotech on the Beach Summit
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
Posted: February 13, 2025 at 2:44 am
HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions.
Read the original post:
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
Posted in Global News Feed
Comments Off on Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
Illuccix® Approved in the United Kingdom
Posted: February 13, 2025 at 2:44 am
MELBOURNE, Australia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET1 imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection).
Continued here:
Illuccix® Approved in the United Kingdom
Posted in Global News Feed
Comments Off on Illuccix® Approved in the United Kingdom
Idorsia publishes the resolutions for the upcoming bondholder meeting
Posted: February 13, 2025 at 2:44 am
Ad hoc announcement pursuant to Art. 53 LR
Excerpt from:
Idorsia publishes the resolutions for the upcoming bondholder meeting
Posted in Global News Feed
Comments Off on Idorsia publishes the resolutions for the upcoming bondholder meeting
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
Posted: February 13, 2025 at 2:44 am
PARIS, FRANCE, 13 February 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year 2024.
See the article here:
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
Posted in Global News Feed
Comments Off on Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
EU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to…
Posted: February 13, 2025 at 2:44 am
ORION CORPORATION PRESS RELEASE 13 FEBRUARY 2024 at 8.00 EET
Read the rest here:
EU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to...
Posted in Global News Feed
Comments Off on EU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to…
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Posted: February 13, 2025 at 2:44 am
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Originally posted here:
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Posted in Global News Feed
Comments Off on Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Vistin Pharma ASA: Fourth quarter and preliminary 2024 financial results
Posted: February 13, 2025 at 2:44 am
Oslo, Norway, 13th of February 2025
Read more from the original source:
Vistin Pharma ASA: Fourth quarter and preliminary 2024 financial results
Posted in Global News Feed
Comments Off on Vistin Pharma ASA: Fourth quarter and preliminary 2024 financial results
Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in…
Posted: February 13, 2025 at 2:44 am
Ad hoc announcement pursuant to Art. 53 LR
See the original post here:
Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in...
Posted in Global News Feed
Comments Off on Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in…